drugset
drugset / Trial / NCT06377540

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

NCT06377540 ↗

Phase 2 Recruiting 28 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.

Timeline

Start
2024-12-04
Primary completion
2026-09-01
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Cytarabine Small molecule 100 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Melphalan Small molecule 140 mg/m2 Intravenous
Background carmustine Small molecule 300 mg/m2 Intravenous

Indications

classic Hodgkin lymphoma disease related to hematopoietic stem cell transplant